State of New Jersey Common Pension Fund D Has $1.87 Million Position in Enovis Co. (NYSE:ENOV)

State of New Jersey Common Pension Fund D boosted its holdings in shares of Enovis Co. (NYSE:ENOV) by 15.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,404 shares of the company’s stock after purchasing an additional 5,801 shares during the quarter. State of New Jersey Common Pension Fund D owned about 0.08% of Enovis worth $1,869,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ENOV. Benjamin F. Edwards & Company Inc. raised its position in shares of Enovis by 28.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock valued at $76,000 after buying an additional 371 shares during the last quarter. Pitcairn Co. grew its holdings in shares of Enovis by 6.8% during the 1st quarter. Pitcairn Co. now owns 6,036 shares of the company’s stock worth $377,000 after purchasing an additional 386 shares in the last quarter. Keeley Teton Advisors LLC increased its position in shares of Enovis by 6.8% during the first quarter. Keeley Teton Advisors LLC now owns 6,936 shares of the company’s stock valued at $433,000 after purchasing an additional 441 shares during the period. US Bancorp DE raised its stake in shares of Enovis by 3.5% in the first quarter. US Bancorp DE now owns 13,043 shares of the company’s stock valued at $815,000 after purchasing an additional 447 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its position in Enovis by 18.6% in the first quarter. Janney Montgomery Scott LLC now owns 4,879 shares of the company’s stock worth $305,000 after purchasing an additional 765 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on ENOV shares. JPMorgan Chase & Co. decreased their target price on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Evercore ISI lowered their price objective on Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 1st. JMP Securities assumed coverage on Enovis in a research report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 target price for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $65.00 price target on shares of Enovis in a research report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $67.00.

Enovis Stock Performance

Shares of NYSE:ENOV opened at $45.55 on Tuesday. The business has a fifty day moving average of $42.44 and a 200-day moving average of $45.12. The firm has a market cap of $2.55 billion, a PE ratio of -20.80 and a beta of 1.91. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. Enovis Co. has a twelve month low of $38.27 and a twelve month high of $65.03.

Enovis (NYSE:ENOV) last announced its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.11. The company had revenue of $505.22 million for the quarter, compared to analyst estimates of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Enovis’s quarterly revenue was up 21.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.56 earnings per share. On average, equities research analysts predict that Enovis Co. will post 2.79 EPS for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.